Mineralys Therapeutics, Inc., a clinical─stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 29/12/2024 11:18
Relief Therapeutics provides update on potential transaction with Renexxion
Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, provided an update on the potential reverse merger with Renexxion,
Articles similaires
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
drugs.com - 02/Jan 22:01
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
drugs.com - 02/Jan 22:01
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Theratechnologies Provides Update on EGRIFTA SV® Supply
financialpost.com - 09/Jan 22:06
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a...
Adcentrx begins patient dosing in phase 1a/b study of ADRX─0405, a potential first─in─class ADC targeting STEAP1 to treat advanced solid tumours
pharmabiz.com - 08/Jan 12:59
Adcentrx Therapeutics (Adcentrx), a clinical─stage biotechnology company advancing innovative protein conjugates for cancer and other...
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
financialpost.com - 09/Jan 22:07
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry...
Assembly Bio announces interim phase 1b results from trial evaluating next─generation CAM candidate ABI─4334 in chronic hepatitis B
pharmabiz.com - 28/12/2024 12:18
Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, announced encouraging interim...
Kistos provides trading and operational update
energy pedia.com - 08/Jan 07:11
Kistos, an independent energy company focused on generating value across the upstream and midstream markets, has provided a trading and operational...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
drugs.com - 30/12/2024 22:01
NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
drugs.com - 30/12/2024 22:01
NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Les derniers communiqués
-
Aucun élément